中国组织工程研究 ›› 2020, Vol. 24 ›› Issue (35): 5715-5722.doi: 10.3969/j.issn.2095-4344.2879

• 组织构建循证医学 evidence-based medicine in tissue construction • 上一篇    下一篇

不同药物治疗原发性骨质疏松症的网状Meta分析

阙敏强1,2,石础硕1,黄英杰1,詹群璋1,霍晨星1,周  驰3,杨仁轩3   

  1. 1广州中医药大学,广东省广州市  5100452广州市正骨医院,广东省广州市  5100453广东省中医院珠海医院,广东省珠海市  519000

  • 收稿日期:2019-11-25 修回日期:2019-12-14 接受日期:2020-01-17 出版日期:2020-12-18 发布日期:2020-10-19
  • 通讯作者: 杨仁轩,博士,主任医师,广东省中医院珠海医院,广东省珠海市 519000
  • 作者简介:阙敏强,男,1984年生,广东省人,主治医师,主要从事关节方面的研究。
  • 基金资助:
    国家自然科学基金(81774339);广东省自然科学基金(2015A030310203);广东省中医药管理局项目(20191099);广东省高水平大学建设项目(A1-AFD018171Z11057)

Network meta-analysis of different drugs for the treatment of primary osteoporosis

Que Minqiang1, 2, Shi Chushuo1, Huang Yingjie1, Zhan Qunzhang1, Huo Chenxing1, Zhou Chi3, Yang Renxuan3   

  1. 1Guangzhou University of Chinese Medicine, Guangzhou 510045, Guangdong Province, China; 2Guangzhou Orthopedic Hospital, Guangzhou 510045, Guangzhou Province, China; 3Zhuhai Hospital of Guangdong Traditional Chinese Medicine Hospital, Zhuhai 519000, Guangdong Province, China

  • Received:2019-11-25 Revised:2019-12-14 Accepted:2020-01-17 Online:2020-12-18 Published:2020-10-19
  • Contact: Yang Renxuan, MD, Chief physician, Zhuhai Hospital of Guangdong Traditional Chinese Medicine Hospital, Zhuhai 519000, Guangdong Province, China
  • About author:Que Minqiang, Attending physician, Guangzhou University of Chinese Medicine, Guangzhou 510045, Guangdong Province, China; Guangzhou Orthopedic Hospital, Guangzhou 510045, Guangzhou Province, China
  • Supported by:
    the National Natural Science Foundation of China, No. 81774339; the Natural Science Foundation of Guangdong Province, No. 2015A030310203; a grant from Guangdong Provincial Administration of Traditional Chinese Medicine, No. 20191099; Guangdong Provincial High-Level University Construction Project, No. A1-AFD018171Z11057

摘要:

文题释义:

阿仑膦酸钠:属于双膦酸盐类药物,可以通过多种作用机制治疗骨质疏松,通过抑制破骨过程,维持骨结构,改善骨矿化程度,有效增加骨皮质的厚度和骨密度,从而提高人体骨骼强度,减轻和预防骨质疏松。

钙剂:通常把以钙元素的生理生化功能及药理学作用为基础、以钙盐为主要成分的制剂称为钙剂。钙剂产品常见为片剂、胶囊、冲剂、粉剂、溶液、针剂等剂型。

背景:临床研究发现阿仑膦酸钠联合降钙素类、钙剂类等其他药物治疗原发性骨质疏松症能提高疗效、降低其不良反应发生率,但尚乏系统评价。

目的:系统评价不同药物治疗原发性骨质疏松症的临床疗效、骨密度、安全性的差异。

方法:计算机检索PubMedCNKIVIP、万方数据库、EmbaseCBMCochrane图书馆,收集不同药物治疗原发性骨质疏松的随机对照试验(RTC)。文献筛选,数据提取,采用Cochrane系统评价及RevMan 5.3对纳入文献进行质量评价;运用马尔科夫链-蒙特卡洛方法,采用Stata 15.0进行贝叶斯网状Meta分析。

结果与结论①共纳入14RCT,共计1 822例患者,涉及阿仑膦酸钠、唑来膦酸、钙剂、钙剂联合唑来膦酸、阿仑膦酸钠联合钙剂、阿仑膦酸钠联合骨肽注射液、钙剂联合骨肽注射液、阿仑膦酸钠联合特立帕肽注射液、鲑鱼降钙素等9种干预措施;②在提高总有效率方面,共涉及9种干预措施,网状Meta排序结果为钙剂联合骨肽注射液>阿仑膦酸钠联合骨肽注射液>阿仑膦酸钠联合唑来膦酸>唑来膦酸>唑来膦酸联合钙剂>鲑鱼降钙素>阿仑膦酸钠联合钙剂>阿仑膦酸钠>钙剂;③在提高治疗后骨密度方面,共涉及5种干预措施,网状Meta排序结果为阿仑膦酸钠联合钙剂>钙剂>钙剂联合唑来膦酸>唑来膦酸>阿仑膦酸钠;④在降低不良反应发生率方面,共涉及7种干预措施,网状Meta排序结果为钙剂>阿仑膦酸钠联合钙剂>阿仑膦酸钠联合骨肽注射液>唑来膦酸联合钙剂>唑来膦酸>阿仑膦酸钠>阿仑膦酸钠联合特立帕肽注射液;⑤结论:骨肽注射液的联合用药能显著提高治疗总有效率,其中钙剂联合骨肽注射液效果最佳;钙剂在提高治疗后骨密度的疗效确切,而联合阿仑膦酸钠具有增效作用,且不良反应的发生率较低,效果最好。

ORCID: 0000-0002-4976-9599(阙敏强)

中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程

关键词: ">原发性骨质疏松, 阿仑磷酸钠, 钙剂, 鲑鱼降钙素, 唑来膦酸

Abstract:

BACKGROUND: Clinical studies have found that alendronate combined with other drugs such as calcitonin and calcium can improve the clinical efficacy on primary osteoporosis and reduce the incidence of adverse reactions, but there is no systematic review.

OBJECTIVE: To systematically evaluate the clinical efficacy, bone density, and safety of different drugs in the treatment of primary osteoporosis.

METHODS: A computer search of PubMed, China Knowledge Network database, VIP, WanFang database, Embase, CBM and the Cochrane Library was performed for randomized controlled trials of different drugs for the treatment of primary osteoporosis. After literature screen and data extraction, the quality of the included literatures was assessed using the Cochrane System and RevMan 5.3. Bayesian network meta-analysis was performed using Stata 15.0 software and Markov chain-Monte Carlo method.

RESULTS AND CONCLUSION: A total of 14 randomized controlled trials with 1 822 patients were enrolled, involving alendronate, zoledronic acid, calcium, calcium combined with zoledronic acid, alendronate combined with calcium, alendronate combined with bone peptide injection, calcium combined with bone peptide injection, alendronate combined with teriparatide injection, and salmon calcitonin. The results of the network meta-analysis showed that there were nine interventions in terms of improving the total effective rate, which ranked as follows: calcium combined with bone peptide injection > alendronate combined with bone peptide injection > alendronate combined with zoledronic acid > zoledronic acid > zoledronic acid combined with calcium > salmon calcitonin > alendronate combined with calcium > alendronate > calcium. In terms of improving bone mineral density after treatment, there are five interventions, which ranked as follows: alendronate combined with calcium > calcium > calcium combined with zoledronic acid > zoledronic acid > alendronate. In terms of reducing the incidence of adverse reactions, seven interventions were involved, which ranked as follows: calcium > alendronate combined with calcium > alendronate combined with bone peptide injection > zoledronic acid combined with calcium > zoledronic acid > alendronate > alendronate combined with teriparatide injection. In conclusion, calcium combined with bone peptide injection is the best measure to improve the total effective rate in the treatment of primary osteoporosis. Calcium is effective in improving bone density after treatment, and calcium combined with alendronate has a synergistic effect, with lowest incidence of adverse reactions and best therapeutic effect.

Key words: primary osteoporosis, alendronate, calcium, salmon calcitonin, zoledronic acid

中图分类号: